

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

Claim 1 (Original): A pharmaceutical composition for preventing or treating skin diseases, which comprises as an active ingredient either an isolated EC SOD protein or a protein exhibiting substantially equivalent physiological activity to the EC SOD protein and having at least 60% sequence homology to amino acid sequence of the EC SOD protein.

Claim 2 (Original): A pharmaceutical composition for preventing or treating skin diseases, which comprises as an active ingredient an expression vector comprising a polynucleotide encoding either an isolated EC SOD protein or a protein exhibiting substantially equivalent physiological activity to the EC SOD protein and having at least 60% sequence homology to amino acid sequence of the EC SOD protein.

Claim 3 (Previously Presented): The pharmaceutical composition of Claim 1, wherein the EC SOD protein is derived from mammals.

Claim 4 (Original): The pharmaceutical composition of Claim 3, wherein the EC SOD protein consisting of an amino acid sequence of SEQ ID NO: 11.

Claim 5 (Previously Presented): The pharmaceutical composition of Claim 1, wherein the skin diseases are selected from the group consisting of skin cancer, pigmentation disease, photoaging, dermatitis, psoriasis, atopy, urticaria and allergy.

Claim 6 (Original): A cosmetic composition for preventing or improving skin diseases, which comprises an isolated EC SOD protein or a protein exhibiting substantially

equivalent physiological activity to the EC SOD protein and having at least 60% sequence homology to amino acid sequence of the EC SOD protein.

Claim 7 (Original): A method for preventing or treating skin diseases, which comprises administering to a subject in need thereof an effective amount of one selected from the group consisting of an isolated EC SOD protein, a protein exhibiting substantially equivalent in physiological activity to the EC SOD protein and having at least 60% sequence homology to amino acid sequence of the EC SOD protein, and an expression vector comprising a polynucleotide encoding each of the proteins.

Claim 8 (Canceled).

Claim 9 (Original): A pharmaceutical composition for preventing or treating skin diseases, which comprises as an active ingredient a cell-transducing EC SOD fusion protein in which a protein transduction domain is fused to either an isolated EC SOD protein or a protein exhibiting substantially equivalent physiological activity to the EC SOD protein and having at least 60% sequence homology to amino acid sequence of the EC SOD protein.

Claim 10 (Original): A pharmaceutical composition for preventing or treating skin diseases, which comprises as an active ingredient an expression vector comprising a polynucleotide sequence encoding a cell-transducing EC SOD fusion protein in which a protein transduction domain is fused to either an isolated EC SOD protein or a protein exhibiting substantially equivalent physiological activity to the EC SOD protein and having at least 60% sequence homology to amino acid sequence of the EC SOD protein.

Claim 11 (Previously Presented): The pharmaceutical composition of Claim 9, wherein the protein transduction domain is selected from the group consisting of a HIV-1 Tat transduction domain, an oligopeptide consisting of 5-12 arginine residues, an oligopeptide

consisting of 5-12 lysine residues, a PEP-1 peptide, an ANTP protein and a VP22 protein.

Claim 12 (Previously Presented): The pharmaceutical composition of Claim 9, wherein the skin diseases are selected from the group consisting of skin cancer, pigmentation disease, photoaging, dermatitis, psoriasis, atopy, urticaria and allergy.

Claim 13 (Original): A cosmetic composition for preventing or improving skin diseases, which comprises as an active ingredient a cell-transducing EC SOD fusion protein in which a protein transduction domain is fused to either an isolated EC SOD protein or a protein exhibiting substantially equivalent physiological activity to the EC SOD protein and having at least 60% sequence homology to amino acid sequence of the EC SOD protein.

Claim 14 (Original): A method for preventing or treating skin diseases, which comprises administering to a subject in need thereof an effective amount of one selected from the group consisting of a cell-transducing EC SOD fusion protein in which a protein transduction domain is fused to either an isolated EC SOD protein or a protein exhibiting substantially equivalent physiological activity to the EC SOD protein and having at least 60% sequence homology to amino acid sequence of the EC SOD protein, and an expression vector comprising a polynucleotide encoding each of the proteins.

Claims 15-19 (Canceled).

Claim 20 (Previously Presented): The pharmaceutical composition of Claim 2, wherein the EC SOD protein is derived from mammals.

Claim 21 (Previously Presented): The pharmaceutical composition of Claim 2, wherein the skin diseases are selected from the group consisting of skin cancer, pigmentation disease, photoaging, dermatitis, psoriasis, atopy, urticaria and allergy.

Claim 22 (Previously Presented): The pharmaceutical composition of Claim 10, wherein the protein transduction domain is selected from the group consisting of a HIV-1 Tat transduction domain, an oligopeptide consisting of 5-12 arginine residues, an oligopeptide consisting of 5-12 lysine residues, a PEP-1 peptide, an ANTP protein and a VP22 protein.

Claim 23 (Previously Presented): The pharmaceutical composition of Claim 10, wherein the skin diseases are selected from the group consisting of skin cancer, pigmentation disease, photoaging, dermatitis, psoriasis, atopy, urticaria and allergy.